Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Zealand PharmaDanish biotech focused on peptide therapeutics. Petrelintide (amylin analog monotherapy, Phase 2, Roche partnership); dapiglutide; survodutide (Phase 3 dual GLP-1/glucagon partnered with Boehringer Ingelheim).
2020-2024
| Asset / Partnership | Phase / Trial | Readout Window + Key Endpoint |
|---|---|---|
| Petrelintide monotherapy Phase 1b (obesity) | Phase 1b; 2023 readouts (pre-Roche deal) | Long-acting amylin receptor agonist; demonstrated dose-related weight reduction in healthy-volunteer + obese cohorts; pharmacokinetic profile supports weekly dosing; supported Phase 2 advancement |
| Petrelintide Phase 2 ZUPREME-1 (obesity) | Phase 2; primary at week 28, 42-week treatment | Mar 5, 2026 topline: up to 10.7% mean weight loss at week 42 vs 1.7% placebo; 493 participants; met its primary endpoint at week 28 with placebo-like tolerability |
| Petrelintide + CT-388 combination (Roche-partnered) | Phase 2 combination | Combination of petrelintide (amylin) with Roche's CT-388 (GLP-1/GIP); mechanistic rationale of complementary amylin + incretin pathways; positioned to compete with NVO CagriSema. Zealand pays Roche $350M for CT-388 in the first combination product |
| Petrelintide Phase 3 obesity (Roche-led) | Phase 3; Roche-led | Roche leads petrelintide Phase 3 development and commercialization under the collaboration; pivotal program and launch timing per Roche guidance |
| Dapiglutide Phase 1b (obesity, 28 weeks) | Phase 1b; June 2025 readout | Long-acting dual GLP-1/GLP-2 receptor agonist (GLP-2 is mechanistically distinct from GIP via intestinal trophic effects); 28-week Phase 1b (June 2025): 11.6% weight loss vs 0.2% placebo; supports Phase 2 advancement |
| Dapiglutide Phase 2 (obesity) | Phase 2; initiated 2025 | Multi-dose Phase 2 obesity cohort; weight-loss primary endpoint; readout 2026-2027 supports Phase 3 advancement + potential partnership decisions |
| Survodutide (Boehringer-partnered) | Phase 3; Boehringer leads | Glucagon/GLP-1 dual agonist; Phase 3 SYNCHRONIZE obesity program (SYNCHRONIZE-1 read out up to 16.6% at 76 weeks, April 2026) + LIVERAGE MASH program ongoing; Zealand earns royalties + milestones per the 2011 partnership |
| Lixisenatide (Sanofi-partnered, legacy commercial) | Commercial (since 2013) | Short-acting GLP-1 RA discovered by Zealand; commercialized by Sanofi as Adlyxin (US) / Lyxumia (EU); declining sales as longer-acting GLP-1 RAs dominate; modest, gradually declining royalty contribution |
| Roche petrelintide deal economics | Signed March 12, 2025 | Upfront $1.65B ($1.4B at close + $250M in anniversary payments over two years); up to $5.3B total including development + sales milestones; 50/50 co-development and co-commercialization in the US and Europe; Zealand pays Roche $350M for CT-388 in the first combination product. Among the largest single-asset obesity partnerships |
| Editorial. Why ZEAL.CO matters | Strategic context | Zealand is a premier peptide-platform pure-play biotech outside the Big Pharma incumbents. The mix of petrelintide (Roche-partnered) + dapiglutide (wholly-owned, novel mechanism) + survodutide royalty (Boehringer Phase 3) + lixisenatide royalty (legacy commercial) creates multi-mechanism, multi-partner cash flows that few standalone biotechs can replicate. The marquee question: as Roche advances petrelintide, does Zealand stay standalone, or does an acquirer move to consolidate the platform? |
$ZEAL.CO
Petrelintide (amylin analog monotherapy, Phase 2, Roche partnership); dapiglutide; survodutide (Phase 3 dual GLP-1/glucagon partnered with Boehringer Ingelheim, MASH and obesity readouts 2026 to 2027).